stockrowBiodexa Pharmaceuticals PLC Unsponsored ADR
BDRX Healthcare Biotechnology
Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.
Follow BDRX
Alert me
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Piotroski F-score
Biodexa Pharmaceuticals PLC Unsponsored ADR's Piotroski F-score for fiscal 2023 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2022.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2023 | 3 | (1.00) |
| FY2022 | 4 | 1.00 |
| FY2021 | 3 | 0.00 |
| FY2020 | 3 | 0.00 |
| FY2019 | 3 | (2.00) |
| FY2018 | 5 | 2.00 |
| FY2017 | 3 | (1.00) |
| FY2016 | 4 | — |
How fiscal 2023’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (88.29%) | (77.02%) | Fail | 0 |
| Positive operating cash flow | (8.49m) | (8.72m) | Fail | 0 |
| Rising return on assets | (88.29%) | (77.02%) | Fail | 0 |
| Cash flow above net income | 314.70k | 752.00k | Pass | 1 |
| Falling long-term leverage | 0.04 | 0.05 | Pass | 1 |
| Rising current ratio | 1.26 | 2.47 | Fail | 0 |
| No new shares issued | 100 | 988,400 | Pass | 1 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.05 | 0.07 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | 3 |
| KPTI Karyopharm Therapeutics Inc. compare | 3 |
| MTNB Matinas Biopharma Holdings, Inc. compare | 1 |
| BBLG Bone Biologics Corp. compare | — |
| PTIX Atrinsic Inc. compare | — |
| ARTL Artelo Biosciences, Inc. compare | — |
| ABPO Abpro Holdings Inc. compare | — |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | — |
| ELAB PMGC Holdings Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover